These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33288848)

  • 1. Stem cell characteristics promote aggressiveness of diffuse large B-cell lymphoma.
    Chang KC; Chen RY; Wang YC; Hung LY; Medeiros LJ; Chen YP; Chen TY; Yang JC; Chiang PM
    Sci Rep; 2020 Dec; 10(1):21342. PubMed ID: 33288848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.
    Cui W; Zheng S; Li X; Ma Y; Sang W; Liu M; Zhang W; Zhou X
    Tumour Biol; 2016 Sep; 37(9):12767-12777. PubMed ID: 27448819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma].
    Wu L; Zhang YZ; Xia B; Li XW; Yuan T; Tian C; Zhao HF; Yu Y; Sotomayor E
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1036-1042. PubMed ID: 29365396
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
    Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
    J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA‑196a‑3p inhibits cell proliferation and promotes cell apoptosis by targeting ADP ribosylation factor 4 in diffuse large B‑cell lymphoma.
    Fu J; Lou X; Wan S; Zhao X; Chen Z; Zhu M; Guo L; Wu D; Wang S
    Oncol Rep; 2021 Feb; 45(2):764-775. PubMed ID: 33416178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.
    Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D
    J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between Chemotactic Factor CCL5 and Diabet-associated Diffuse Large B Cell Lymphoma].
    Zhang JC; Liu FR; Hu HX; He F; Tu Y; Wei B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1325-30. PubMed ID: 26524031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
    Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
    Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome.
    Yeh YM; Chang KC; Chen YP; Kao LY; Tsai HP; Ho CL; Wang JR; Jones D; Chen TY
    Histopathology; 2010 Dec; 57(6):785-95. PubMed ID: 21166693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
    Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
    Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
    Kim SW; Oleksyn DW; Rossi RM; Jordan CT; Sanz I; Chen L; Zhao J
    Blood; 2008 Feb; 111(3):1644-53. PubMed ID: 18025152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
    Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
    Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels.
    Zhong W; Zhu Z; Xu X; Zhang H; Xiong H; Li Q; Wei Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):73. PubMed ID: 30755239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
    Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
    Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex.
    Dai YH; Hung LY; Chen RY; Lai CH; Chang KC
    Transl Res; 2016 Sep; 175():129-143.e13. PubMed ID: 27150054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
    Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
    Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link.
    Kuttler F; Valnet-Rabier MB; Angonin R; Ferrand C; Deconinck E; Mougin C; Cahn JY; Fest T
    Leukemia; 2002 Apr; 16(4):726-35. PubMed ID: 11960356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.